Ellsworth Advisors LLC Invests $670,000 in Theravance Biopharma, Inc. $TBPH

Ellsworth Advisors LLC bought a new stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 33,332 shares of the biopharmaceutical company’s stock, valued at approximately $670,000.

A number of other institutional investors have also recently made changes to their positions in TBPH. Baader Bank Aktiengesellschaft bought a new stake in Theravance Biopharma during the third quarter worth approximately $781,000. Hillsdale Investment Management Inc. bought a new stake in shares of Theravance Biopharma in the 3rd quarter valued at approximately $4,536,000. Inspire Investing LLC bought a new stake in shares of Theravance Biopharma in the 3rd quarter valued at approximately $1,074,000. Assenagon Asset Management S.A. boosted its holdings in shares of Theravance Biopharma by 1,629.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 414,715 shares of the biopharmaceutical company’s stock worth $6,055,000 after purchasing an additional 390,735 shares during the period. Finally, WINTON GROUP Ltd purchased a new position in shares of Theravance Biopharma in the 3rd quarter worth approximately $1,118,000. Institutional investors own 99.10% of the company’s stock.

Wall Street Analysts Forecast Growth

TBPH has been the topic of several recent research reports. HC Wainwright increased their price target on Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Oppenheimer lowered shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 5th. Zacks Research upgraded shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Thursday, March 19th. BTIG Research reissued a “buy” rating and issued a $21.00 target price on shares of Theravance Biopharma in a research note on Friday, March 20th. Finally, B. Riley Financial restated a “neutral” rating and issued a $14.00 target price (down from $28.00) on shares of Theravance Biopharma in a report on Wednesday, March 4th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, Theravance Biopharma currently has an average rating of “Moderate Buy” and a consensus target price of $21.33.

Insider Buying and Selling

In related news, SVP Rhonda Farnum sold 31,067 shares of the firm’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $13.96, for a total value of $433,695.32. Following the transaction, the senior vice president owned 232,699 shares of the company’s stock, valued at $3,248,478.04. This trade represents a 11.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 6.90% of the stock is owned by corporate insiders.

Theravance Biopharma Trading Up 1.1%

NASDAQ:TBPH opened at $16.02 on Friday. Theravance Biopharma, Inc. has a twelve month low of $7.90 and a twelve month high of $21.03. The company has a market cap of $824.87 million, a price-to-earnings ratio of 7.89 and a beta of 0.17. The stock has a fifty day simple moving average of $17.13 and a 200-day simple moving average of $16.94.

Theravance Biopharma Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.